Introduction
============

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin\'s lymphomas (NHL) and is characterized by a relatively high frequency of extra-nodal spread[@B1]. Bone marrow involvement is diagnosed in approximately 15% of newly diagnosed DLBCL and accounts for 1 point in the International Prognostic Index (IPI) score.

Bone marrow biopsy (BMB) has been the gold standard for bone marrow evaluation for many decades and is still recommended in the conventional staging of all patients with DLBCL by guidelines[@B4]. However, BMB is an invasive and painful procedure that has a small but non-negligible risk of complications such as pain, anxiety, hemorrhage and infection[@B5], [@B6]. Furthermore, the small sample size from biopsy or the BMI focal status may cause the omission of BMI lesions, which is the main reason for the poor sensitivity of BMB[@B2].

^18^F-FDG PET/CT, as a noninvasive whole-body metabolic imaging technique, is now routinely applied in the clinical work-up of DLBCL, especially in staging, restaging as well as prognostic analysis, owing to its ability to accurately evaluate both nodal and extra-nodal disease sites[@B7]-[@B9]. The diagnostic and prognostic value of PET/CT-ascertained BMI remains controversial in the recent retrospective studies[@B2], [@B10]-[@B14]. The lack of standardized interpretation of diffuse BM pattern could explain the conflicting conclusions. As we all know, focally increased FDG uptake of BM is generally accepted as a sign of BMI, but it is difficult to identify whether the diffuse pattern is BMI. The diffuse BM FDG uptake has been extensively reported to be associated with both malignant infiltration and benign etiologies([@B15]-[@B18]). Up to now, there has been no consensus on the interpretation of diffuse BM pattern in DLBCL. Unlike the previous studies, our large sample, single-center study was designed to determine the prognostic meaning of different BM FDG uptake patterns of PET/CT. In the present study, the focal, diffuse and normal BM uptake patterns in DLBCL were investigated individually instead of simply being interpreted as BMI or non-BMI. To our knowledge, very little was found in the literature about the prognostic value of PET/CT-based BM patterns in DLBCL.

Materials and Methods
=====================

Study population and data extraction
------------------------------------

The study has been approved by the institutional review board of Ren Ji Hospital Shanghai Jiao Tong University School of Medicine. 193 consecutive patients undergoing pre-therapy staging for newly diagnosed DLBCL in our PET/CT center between January 2007 and June 2016 were retrospectively enrolled in this study. All patients were treated with 6-8 cycles of R-CHOP therapy. Our study exclusion criteria were as follows: patients with transformed lymphoma or coexistence of another lymphoma subtype in the diagnostic biopsy, those who had received hematopoietic growth factor, chemotherapy or glucocorticoids prior to PET/CT imaging, those with time interval between PET/CT and BMB exceeding 30 days. Patient data were recorded in details as follows: age, sex, Ann Arbor stage, International Prognostic Index, presence of B symptoms, extra-nodal involvement. All of them were extracted from medical records. Patient follow-up data were searched to detect presence of disease progression and progression-free survival times. PFS and OS were calculated from diagnosis to disease progression or death from any cause.

^18^F -FDG PET/CT Acquisition
-----------------------------

The study was performed by dedicated PET/CT scanners (2007-2012, GE Discovery LS PET/CT system; after 2012, Siemens Biograph PET/CT system) according to standard protocol. All patients enrolled have received an intravenous injection of 0.1mCi/kg ^18^F-FDG after fasting for at least 6 hours. The blood glucose level of each patient was strictly confirmed under 150 mg/dL right before the injection. The patients were free to rest on the bed and relax for 45 to 60 min after the FDG administration. Diagnostic-quality unenhanced CT images were acquired before PET data acquisition and were used for attenuation correction in the PET image reconstruction.

Identification of BM uptake patterns by PET/CT
----------------------------------------------

The CT, PET, and fused PET/CT images were reviewed in transaxial, coronal, and sagittal planes along with maximum intensity projection whole-body images. Two experienced nuclear medicine physicians (Chen Y and Liu J) blinded to treatment outcome and other clinical information, analyzed PET/CT images visually and semi-quantitatively with standardized uptake value.

Focal BM uptake was defined as focally increased FDG uptake higher than normal liver FDG uptake (Figure [1](#F1){ref-type="fig"}A). Diffusely increased FDG uptake was interpreted as diffuse homogenous FDG uptake higher than that of normal liver (Figure [1](#F1){ref-type="fig"}B). Normal uptake was considered as a mild homogenous uptake lower than that of normal liver (Figure [1](#F1){ref-type="fig"}C). Structural abnormalities including osteolytic, osteosclerotic lesion, mixed lesions or no abnormalities were observed through CT images.

Bone marrow biopsy
------------------

In our hospital, unilateral iliac crest trephine biopsy and marrow aspirate were routinely performed in all newly diagnosed DLBCL patients. All BMBs were performed according to standard procedures and the BMB results were obtained from the pathology reports. BMB material was routinely formalin fixed and paraffin embedded and subsequently evaluated morphologically on the basis of a standard immunohistochemistry, including antibodies to identify CD3, CD79a, and CD20-positive cells.

Data analysis
-------------

Differences in clinicopathological factors between groups were analyzed by chi-square test, T test and Wilcoxon test, according to the types of variables. The prognostic significance of the BM uptake patterns was derived by the Kaplan-Meier method and the between groups difference was evaluated by Log-rank test. Cox regression model was used to identify independently predictive variables from clinical, pathologic and imaging variables. The hazard ratio (HR) and its 95%CI were also calculated by Cox-regression model. All the statistical analyses were performed using SPSS, version 20.0 (IBM corporation, NY, USA). Double sided *p* values \<0.05 were considered statistically significant.

Results
=======

Patient characteristics
-----------------------

193 patients newly diagnosed with DLBCL were included in our retrospective study. The median age was 58y (range, 14-87y), and the ratio of male to female was 0.87. According to Ann Arbor Stage, the number of patients in Stage I, II, III and IV were 31 (16.1%), 53 (27.5%), 22(11.4%) and 87 (45%), respectively. After 6-8 cycles of R-CHOP chemotherapy, 159 (82.4%) out of 193 patients achieved complete remission (CR) or partial remission (PR). Detailed baseline clinical characteristics were summarized in Table [1](#T1){ref-type="table"}.

Correlations between PET/CT and BMB
-----------------------------------

We separated the patients into 3 groups according to their BM uptake pattern on baseline PET/CT. 147 (76.2%) patients had normal FDG uptake (nPET) on bone marrow (compared with normal liver). In patients with BM uptake higher than normal liver, 28 (14.5%) patients were presented with focal uptake (fPET+), and 18 (9.3%) patients had diffuse uptake on BM (dPET+). BMB was routinely performed in all the patients. BMB positive was found in 14 (7.3%) out of 193 patients. Of fPET+ and dPET+ patients, BMB positive accounted for 36% (10/28) and 17% (3/18), respectively. For nPET patients, BM involvement assessed by BMB was found only in 1 out of 147 patients. The case contribution of BM involvement assessed by PET/CT BM uptake pattern and BMB is shown in Figure [2](#F2){ref-type="fig"}. When using both fPET+ and BMB+ as reference standards, the sensitivity, negative predictive value and accuracy of PET/CT and BMB were 87.5%, 97.6% and 97.9% versus 43.8%, 89.9% and 90.7%, respectively. We also analyzed the relationship between different BM uptake patterns and BMB results. fPET+ patients had a larger proportion of positive BMB compared with fPET- (dPET+ or nPET) patients (35.7% vs 2.4%, p\<0.001), while dPET+ patients had a relatively higher proportion of positive BMB than dPET- patients without significant difference (16.7% vs 6.3%, p=0.106) (Table [2](#T2){ref-type="table"}).

Characteristics and prognosis in relation to different BM patterns
------------------------------------------------------------------

Table [2](#T2){ref-type="table"} reveals the differences in clinical characteristics between different groups. Compared with fPET- patients, fPET+ patients had higher frequency of B symptoms (p=0.007) and lower level of hemoglobin (p=0.025). dPET+ patients were proved to have lower hemoglobin levels than dPET- patients (p=0.005). Both fPET+ and dPET+ patients tended to have higher ESR level than the overall population (p=0.063 and 0.097, respectively). No differences were found in age and WBC level between groups. We also compared SUVmax of BM in different groups in order to investigate whether BM metabolic status was associated with BM patterns or BMB results (Figure [3](#F3){ref-type="fig"}). We found fPET+ had higher SUVmax than dPET+ (12.6±7.4 vs 4.3±1.3, p\<0.001). SUVmax of fPET+/BMB+ was similar to that of fPET+/BMB- (14.3±6.9 vs 11.7±7.6, p=0.394), but was significantly higher than that of dPET+/BMB+ (14.3±6.9 vs 5.7±1.8, p=0.005). Interestingly, significant difference in SUVmax was also revealed between dPET+/BMB+ and dPET+/BMB- (5.7±1.8 vs 4.0±1.0, p=0.024).

After a median follow-up of 30 (12-124) months, 47 (24%) out of 193 patients had disease progression or relapse, and 20 (10%) patients died. Figure [4](#F4){ref-type="fig"}-[5](#F5){ref-type="fig"} shows PFS and OS Kaplan Meier Curves of patients in groups. fPET+ patients had inferior 3y-PFS compared with nPET patients (32.7% vs 81.5%, p\<0.001), but dPET+ had similar 3y-PFS to nPET (80.5% vs 81.5%, p=0.701). 3y-PFS of fPET+ and fPET- were 32.7% and 76.2, respectively (p\<0.001), while 3y-PFS of BMB+ and BMB- were 60.6% and 81.2%, respectively (p=0.205) (Figure [6](#F6){ref-type="fig"}A). We further analyzed PFS of different BM patterns in patients with negative BMB. We found a poor 3y-PFS of fPET+/BMB- patients compared with nPET/BMB- and fPET-/BMB- patients (0% vs 81.4%, p\<0.001; 0% vs 82.2%, p\<0.001), and we found no difference between dPET+/BMB- and nPET/BMB- (90% vs 81.4%, p=0.618). The OS Kaplan Meier Curves also revealed similar results to PFS curves. In univariate analysis, stage III/IV (HR 13.454, p\<0.001), B symptoms (HR 3.687, p\<0.001), IPI\>2 (HR 8.061, p\<0.001) and fPET+ (HR 4.428, p\<0.001) were significantly related to poor PFS, while stage III/IV (HR 54.711, p=0.030), BMB+ (HR 3.969, p=0.014), IPI\>2 (HR 103.927, p=0.015) and fPET+ (HR 3.699, p=0.005) were associated with poor OS. In multivariate analysis of PFS, stage III/IV (HR 4.909, p=0.026) and fPET+ (HR 2.270, p=0.025) were independent predictors. There were no independent predictors in the multivariate analysis of OS (Table [3](#T3){ref-type="table"}).

Discussions
===========

This retrospective study with large sample from single-center aimed to investigate the prognostic significance of BM assessment in newly diagnosed DLBCL based on FDG uptake pattern from PET/CT imaging compared with BMB.

Our study first gave a detailed description of BM FDG uptake patterns to assess bone marrow status in DLBCL patients. In a series of 193 patients, 28 patients had fPET+ and 18 patients had dPET+ while the other 147 patients had nPET. We found BMB+ was not concordant with fPET+, as BMB+ only accounted for 36% (10/28) of fPET+ patients. Since fPET+ was generally interpreted as BMI, this missing rate of 64% (18/28) questioned the value of the BMB as a single examination for assessing BMI of DLBCL. The small size of the BMB sample and the focal disease of BMI away from the iliac crest are reasonable explanations for this result.

The finding of dPET+ of BM is not rare in DLBCL. In some studies, this kind of BM pattern was interpreted negative for BMI[@B2], while some other researchers considered it as positive[@B11], [@B19], [@B20]. The disagreement on the interpretation made it difficult to accurately assess the value of dPET+ in DLBCL. In our study, we separated 18 patients with dPET+ as a single group. In dPET+ group, three patients were BMB positive but no one was upstaged by BMB. No significant difference was found in the ratio of BMB positive between dPET+ patients and the overall population. We observed a clear correlation between dPET+ and low hemoglobin level, which suggested that dPET+ was mostly related to reactive myelopoiesis. The fact that ESR level tended to be higher in dPET+ patients than in the overall population implied dPET+ might also be associated with inflammation. Interestingly, the BM SUVmax of dPET+/BMB+ patients was higher than dPET+/BMB- patients but lower than fPET+ patients, which may be attributed to the diffuse but low-density malignant infiltration of BM.

In our study, PET/CT only missed one BMB positive patient out of 147 nPET patients, who had already been staged as stage IV according the PET/CT imaging. It means we must do 147 BMBs to catch only one BMI missed by PET/CT. This may suggest that BMB could be safely omitted in nPET patients, because of extremely high negative predictive value of nPET. A meta-analysis from Adams et al. suggested that BMI cannot be excluded for patients with negative PET findings on BM, because they found that PET/CT can miss BMI in about 3.1% of patients[@B21]. We think this opinion not appropriate because they didn\'t mention whether BMB+ upstaged nPET patients and how much patients would benefit from BMB. And the heterogeneity of the nPET reference in their analysis also made the conclusion not convincing enough.

The prognostic value of BMI based on FDG PET/CT is still not demonstrated clearly. Some studies indicated the excellent prognostic value of PET-BMI in DLBCL patients [@B2], [@B11], [@B13], [@B22], while some studies drew the opposite conclusion [@B14], [@B19], [@B20]. In their studies, the diffuse BM pattern was interpreted differently, thus more or less leading to different conclusions. We have already demonstrated that the diffuse BM pattern was associated with anemia, inflammation or malignant infiltration. It\'s difficult to accurately identify BMI from the diffuse BM pattern. Liang et al defined the diffuse BM pattern with concomitant disappearance of BM uptake on post-therapy PET as BMI[@B13]. In our opinion, this definition is not appropriate because post-therapy PET can also exhibit diffuse BM uptake caused by the administration of hematopoietic cytokines and myeloid hyperplasia[@B15], [@B23]. So we explored the prognostic value of PET/CT-based BM uptake pattern instead of PET-ascertained BMI. Our results showed fPET+ patients had significant inferior prognosis compared with nPET patients, while 3y-PFS of BMB+ and BMB- didn\'t exist statistical difference. We further found fPET+ was able to identified the patients with poor prognosis from BMB negative patients (Figure [4](#F4){ref-type="fig"}C,4D,5C,5D). In multivariate analysis of PFS, only stage III/IV and fPET+ were proved to be independent predictors of PFS. To sum up, the focal pattern of BM is of better prognostic value than BMB. Unlike Chen-Liang \'s and Khan\'s results, we didn\'t obtain the result that BMB was independently predictive for PFS and OS[@B14], [@B19]. We found the BMB+ rate in our study and previous studies differed in a considerable disparity, ranging from 6.0% to16.4%[@B2], [@B24]. This heterogeneity may lead to different conclusions on prognostic value of BMB. But fPET+ failed to independently predict OS in the present study. The relatively small number of deaths during follow-up in our study (10.4%, 20/193) may be the main reason for this result. Then we evaluated the prognostic value of dPET+. Although there was a small portion of BMB+ in dPET+ group, no significant difference in patients\' survival was found between dPET+ and nPET groups.

In conclusion, 18F- FDG PET/CT could be a reliable tool for evaluating BM status and predicting prognosis in DLBCL patients. Only focal uptake pattern of BM, not diffuse pattern, is an independent predictor of inferior outcomes. Compared with BM pattern assessed by PET/CT, BMB seems to be unnecessary for the management of DLBCL as its low accuracy and limited ability of prognostic prediction. Further efforts should be made to confirm the prognostic value of PET/CT-based BM patterns in prospective and multicenter studies.
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^18^F-FDG PET/CT

:   ^18^F-fluorodeoxyglucose positron emission tomography /computed tomography

DLBCL

:   diffuse large B-cell lymphoma

BMI

:   bone marrow involvement

BMB

:   bone marrow biopsy

PFS

:   progression-free survival

OS

:   overall survival

R-CHOP

:   rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

ESR

:   erythrocyte sedimentation rate

NHL

:   non-Hodgkin\'s lymphoma

IPI

:   International Prognostic Index

GCB

:   germinal center B-cell like

IQR

:   interquartile range

MIP

:   maximum intensity projection.

![MIP images of focal (A), diffuse (B) and normal (C) FDG uptake patterns of bone marrow in DLBCL.](jcav09p1231g001){#F1}

![The case contribution of BMI assessed by PET/CT-based BM pattern and BMB](jcav09p1231g002){#F2}

![Comparison of SUVmax on BM between different groups.](jcav09p1231g003){#F3}

![PFS Kaplan Meier Curves of DLBCL patients in groups. A. Comparison of PFS between different BM patterns. 3y-PFS of dPET+ vs nPET was 80.5% vs 81.5%, p=0.701; 3y-PFS of fPET+ vs nPET was 32.7% vs 81.5%, p\<0.001. B. Comparison of PFS between focal pattern and non-focal pattern. 3y-PFS of fPET+ vs fPET- was 32.7% vs 81.4%, p\<0.001. C. Comparison of PFS between different BM patterns in BMB negative patients. 3y-PFS of dPET+ vs nPET was 90% vs 81.4%, p=0.618; 3y-PFS of fPET+ vs nPET was 0% vs 81.4%, p\<0.001. D. Comparison of PFS between focal pattern and non-focal pattern in BMB negative patients. 3y-PFS of fPET+ vs fPET- was 0% vs 82.2%, p\<0.001.](jcav09p1231g004){#F4}

![OS Kaplan Meier Curves of DLBCL patients in groups. A. Comparison of OS between different BM patterns. 3y-OS of dPET+ vs nPET was 94.1% vs 90.6%, p=0.809; 3y-OS of fPET+ vs nPET was 69.4% vs 90.6%, p\<0.001. B. Comparison of OS between focal pattern and non-focal pattern. 3y-OS of fPET+ vs fPET- was 69.4% vs 90.9%, p=0.003. C. Comparison of OS between different BM patterns in BMB negative patients. 3y-OS of dPET+ vs nPET was 100% vs 90.6%, p=0.300; 3y-OS of fPET+ vs nPET was 76.9% vs 90.6%, p=0.037. D. Comparison of OS between focal pattern and non-focal pattern in BMB negative patients. 3y-OS of fPET+ vs fPET- was 76.9% vs 91.3%, p=0.023.](jcav09p1231g005){#F5}

![PFS and OS Kaplan Meier Curves between BMB positive and BMB negative patients. A. Comparison of PFS between BMB+ and BMB- patients. 3y-PFS of BMB+ vs BMB- was 60.6% vs 76.1%, p=0.205. B. Comparison of OS between BMB+ and BMB- patients. 3y-OS of BMB+ vs BMB- was 61% vs 89.8%, p=0.008.](jcav09p1231g006){#F6}

###### 

Baseline clinical characteristics of DLBCL patients

  Patient characteristics (N=193)   No. of patients (%)
  --------------------------------- ---------------------
  Age                               
  ≤60y                              99 (51.3)
  \>60y                             94 (48.7)
  Male Sex                          90 (46.6)
  Ann Arbor Stage                   
  I                                 31 (16.1)
  II                                53 (27.5)
  III                               22 (11.4)
  IV                                87 (45.0)
  B symptom                         106 (54.9)
  IPI score                         
  0-2                               110 (57)
  3-5                               83 (43)
  Subtype\*                         
  GCB                               45 (23.3)
  Non-GCB                           95 (49.2)

\*Missing data in 53 patients

###### 

Clinical-imaging correlations according to bone marrow uptake patterns

  ---------------------------------------------------------------------------------------------------------
  Characteristics     fPET             dPET                                                         
  ------------------- ---------------- --------------- --------- ----------------- ---------------- -------
  BMB+ (%)            10 (35.7)        4(2.4)          \<0.001   3 (16.7)          11 (6.3)         0.106

  Age (Mean±SD)       60±13            57±15           0.336     56±14             58±15            0.553

  Male sex (%)        12 (42.9)        78 (47.2)       0.665     3 (16.7)          87 (49.7)        0.007

  IV Stage (%)        28 (100)         59 (35.8)       \<0.001   11 (61.1)         76 (43.4)        0.151

  B symptoms (%)      22 (78.5)        84 (50.9)       0.007     12 (66.7)         94 (53.7)        0.293

  Progression (%)     16 (57.1)        31 (18.8)       \<0.001   4 (22.2)          43 (24.6)        0.825

  Death (%)           7 (25)           13 (7.9)        0.006     1 (5.6)           19 (10.9)        0.482

  WBC (×10^9^/L)\     5.3 (4.5, 7.9)   5.8 (4.6,7.1)   0.698     5.7 (4.4, 14.2)   5.8 (4.6, 7.1)   0.290
  Median (IQR)                                                                                      

  Hemoglubin (g/dL)   110±26           120±21          0.025     105±28            120±20.4         0.005

  ESR (mm/h)\         29 (12, 67)      18 (10, 34)     0.063     33 (10, 50)       19 (11, 34)      0.097
  Median (IQR)                                                                                      
  ---------------------------------------------------------------------------------------------------------

###### 

Univariate and multivariate analysis of PFS and OS.

  ----------------------------------------------------------------------------------------
  Univariate\     PFS                     OS                                       
  analysis                                                                         
  --------------- ----------------------- ------------- -------------------------- -------
  Age\>60y        1.319 (0.744-2.338)     0.343         1.540 (0.638-3.720)        0.337

  Stage III/IV    13.454 (4.176-43.343)   \<0.001       54.711 (1.463-2046.131)    0.03

  B symptoms      3.687 (1.783-7.627)     \<0.001       2.370 (0.861-6.523)        0.095

  IPI score\>2    8.061 (3.762-17.272)    \<0.001       103.927 (2.508-4306.619)   0.015

  Non-GCB         1.035 (0.495-2.164)     0.928         1.095 (0.343-3.496)        0.878

  BMB +           1.801 (0.712-4.558)     0.214         3.969 (1.324-11.895)       0.014

  fPET +          4.428 (2.405-8.153)     \<0.001       3.699 (1.472-9.298)        0.005

  dPET +          0.870 (0.313-2.429)     0.792         0.574 (0.077-4.287)        0.588

  Multivariate\   PFS                     OS                                       
  analysis                                                                         

  HR (95% CI)     p                       HR (95% CI)   p                          

  Stage III/IV    4.909 (1.206-19.986)    0.026         /                          /

  fPET +          2.270 (1.106-4.658)     0.025         /                          /
  ----------------------------------------------------------------------------------------
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